Answers are grounded in this paper and cite their sources.
The addition of bedaquiline to a preferred background regimen for 24 weeks resulted in faster culture conversion and significantly more culture conversions at 120 weeks, as compared with placebo. There were more deaths in the bedaquiline group than in the placebo group. (Funded by Janssen Pharmaceuticals; TMC207-C208 ClinicalTrials.gov number, NCT00449644.).
No takes yet. Share an insight, caveat, or question.
Diacon et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: